Diagonal Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care · 28 employees
Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver li
Funding history
- Series B — $125.0M — Jan 2026
- Series A — $128.0M — Apr 2024
Recent signals
- Jan 08, 2026: Raised $125.0M in Series B
- Jul 08, 2025: Diagonal Therapeutics Appoints John Lee as Chief Medical Officer
- Apr 03, 2024: Raised $128.0M in Series A
See plans & pricing → Track Diagonal Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.